Latest filing published 14 Jul 2026 for CG Oncology, Inc., €1.6M.
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Filings by James Mulay span 2 companies, the busiest being CG Oncology, Inc. and Fulgent Genetics, Inc. The record holds 31 filings, for trades running from 26 October 2016 to 10 July 2026.
Every open-market trade on record is a sale: 16 sales worth €5.4M. The rest of the record consists of 2 share grants and 13 option exercises. In 2026 alone, the filings show no purchases and 8 sales.
The record was last updated on 14 July 2026 with an open-market sale (€1.6M) in CG Oncology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. The legal deadline for a Form 4 is two business days after the transaction. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
18 of 18 declarations